The world's first fully absorbable, patch-based large-bore percutaneous closure device is now available to European physicians and patients
Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the European launch of the PerQsealclosure device for large-bore transcatheter procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181109005102/en/
Novel transcatheter endovascular procedures, including transcatheter aortic valve replacement (TAVR), thoracic endovascular aneurysm repair (TEVAR), and endovascular abdominal aneurysm repair (EVAR), require large-bore femoral artery access. Closure of these large-bore access sites is challenging and has been associated with significant vascular and bleeding complications.
PerQseal is the first sutureless, fully absorbable synthetic implant for large-bore arterial punctures. The PerQseal technology consists of an intravascular patch that seals the vessel from the inside, returning the artery to its natural state.
"Closing the artery has been a concern since we started using transcatheter techniques for valve implantation," says Prof. Horst Sievert, of the CardioVascular Center in Frankfurt, Germany. "The PerQseal device is a very innovative solution for closing large holes, and we are enthusiastic to make it part of our armamentarium."
"We're excited that the PerQseal device is now widely available to European physicians, providing a safe and simple option for the closure of large puncture holes that leaves behind no sutures, metal implants, or collagen," said Gerard Brett, co-founder and CEO of Vivasure Medical. "This commercial launch is a key milestone for Vivasure as we journey to enable better patient outcomes in fully percutaneous large-bore endovascular procedures."
"In my first clinical experience with PerQseal, I found the device intuitive and well controlled, which helped me quickly learn how to use the technology safely and successfully," said Dr. Saib Khogali, Heart Lung Centre, New Cross Hospital Wolverhampton, United Kingdom. "I believe the PerQseal has the potential to be an important large-hole closure device in many TAVR and EVAR patients."
About Vivasure Medical
Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. Vivasure operates a fully integrated R&D and ISO 13485 certified manufacturing facility and is backed by leading international medtech investors. For more information, please visit www.vivasuremedical.com.
The PerQseal is not available for sale in the United States.
for Vivasure Medical
Sierra Smith, 408-540-4296